OLGC Orthologic (MM)

Chrysalis BioTechnology Presents at Southwest Bio Conference Chrysalin(R) Continues Advancement in Multiple Indications GALVESTON, Texas, Dec. 10 /PRNewswire/ -- Chrysalis BioTechnology, Inc., today presented a business and product development update at the fourth annual Southwest Bio Venture Conference & Symposium in Houston. Dennis McWilliams, Chief Operating Officer, reported that the Company's patented lead drug candidate, Chrysalin(R), is progressing in clinical trials for the treatment of bone fractures and diabetic ulcers, and that the Company has added additional peptide drug candidates to its product development pipeline. "Phase 3 evaluation of Chrysalin used to accelerate the healing of bone fractures has progressed under the direction of our corporate partner, OrthoLogic Corporation (NASDAQ:OLGC)," stated McWilliams. "OrthoLogic is focused on commercializing several potential orthopedic indications of Chrysalin, including bone fractures, spine fusion, and cartilage." In addition to the products for orthopedics, Chrysalis has retained the rights to active Chrysalin programs in chronic diabetic ulcers, currently in Phase 2, and additional programs in dental bone regeneration and cardiovascular repair. Beyond the Chrysalin peptide, the Company has added two novel patented peptide based drug candidates for infection control and cancer metastasis. All of these potential products address sizeable markets and represent additional partnering opportunities. Chrysalin, also known as TP508, is a 23-amino acid synthetic peptide that represents a portion of the human enzyme thrombin, a naturally occurring molecule that plays a critical role in the body's ability to heal its own wounds, including the initiation of blood clotting and tissue repair. Chrysalin interacts directly with selected thrombin receptors on cells involved in tissue repair, triggering the release of growth factors and other wound healing signals, without affecting blood clotting. Chrysalis BioTechnology, Inc., is a privately held biopharmaceutical company located in Texas developing synthetic peptide compounds for tissue repair and regeneration. The Company's lead compound, Chrysalin(R), is in a Phase 3 clinical trial for bone fracture healing and a Phase 2 trial for spine fusion, each under an exclusive license agreement with OrthoLogic Corporation. The Company intends to initiate a Phase 2 clinical trial for the treatment of chronic diabetic ulcers during 2004. For more information visit the Chrysalis BioTechnology website at http://www.chrysalisbio.com/. This release was issued through Major Newswire (http://www.majornewswire.com/) DATASOURCE: Chrysalis BioTechnology, Inc. CONTACT: Dennis McWilliams of Chrysalis BioTechnology, Inc., +1-409-750-9251 or +1-409-771-9059 Web site: http://www.majornewswire.com/ Web site: http://www.chrysalisbio.com/

Copyright